NBIS vs LGND

For growth investors, Nebius Group N.

V. (NBIS) is the stronger pick with 350. 9% revenue growth year-over-year, versus 27. 3% for Ligand Pharmaceuticals Incorporated (LGND). Nebius Group N. V. (NBIS) offers the better valuation at 1773. 5x trailing P/E, making it the more compelling value choice. Analysts rate Nebius Group N. V. (NBIS) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Nebius Group N.

V. (NBIS) delivered a total return of +875. 5%, compared to +83. 9% for Ligand Pharmaceuticals Incorporated (LGND). Over 10 years, the gap is even starker: NBIS returned +823. 8% versus LGND's +73. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ligand Pharmaceuticals Incorporated (LGND) is the lower-risk stock at 0.

99β versus Nebius Group N. V. 's 3. 07β — meaning NBIS is approximately 210% more volatile than LGND relative to the S&P 500. On balance sheet safety, Ligand Pharmaceuticals Incorporated (LGND) carries a lower debt/equity ratio of 1% versus 106% for Nebius Group N. V. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nebius Group N.

V. (NBIS) is pulling ahead at 350. 9% versus 27. 3% for Ligand Pharmaceuticals Incorporated (LGND). On earnings-per-share growth, the picture is similar: Nebius Group N. V. grew EPS 104. 8% year-over-year, compared to -107. 5% for Ligand Pharmaceuticals Incorporated. Over a 3-year CAGR, NBIS leads at 239. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nebius Group N.

V. (NBIS) is the more profitable company, earning 19. 2% net margin versus -2. 4% for Ligand Pharmaceuticals Incorporated — meaning it keeps 19. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LGND leads at -13. 5% versus -112. 5% for NBIS. At the gross margin level — before operating expenses — LGND leads at 93. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for LGND: 15.

1% to $267. 75.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

99)). Nebius Group N. V. (NBIS) carries a higher beta of 3. 07 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LGND: +73. 0%, NBIS: +823. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NBIS (Communication Services) and LGND (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.